🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Genetically engineered mouse models to investigate the liposarcoma microenvironment
Organization UNIVERSITY OF MICHIGAN AT ANN ARBORLocation ANN ARBOR, UNITED STATESPosted 1 May 2024Deadline 30 Apr 2026 ⚠️
NIHUS FederalResearch GrantFY2025AbscissionAntioncogene Protein p53AutologousB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBiologyBloodBlood Reticuloendothelial SystemBody TissuesC57BL/6 MouseCancersCell LineCellLineCellular Tumor Antigen P53Checkpoint inhibitorClinical TreatmentClinical TrialsCommunitiesComplexDNA mutationDedifferentiated LiposarcomasDevelopmentDiseaseDisorderDouble MinutesEctopic lymphoid organEctopic lymphoid structureEvolutionExcisionExtirpationGEM modelGEMM modelGeneralized GrowthGeneticGenetic ChangeGenetic defectGenetic mutationGenetically Engineered MouseGenomicsGrowthHistologicHistologicallyHistologyHumanImmuneImmune checkpoint inhibitorImmune mediated therapyImmune responseImmunesImmunityImmunocompetentImmunologically Directed TherapyImmunotherapeutic agentImmunotherapyIncidenceKineticsLeadLymphocytic NeoplasmLymphocytic TumorLymphocytic and Plasma Cell NeoplasmLymphocytic and Plasma Cell TumourLymphocytic and Plasmacytic NeoplasmLymphoid TumorLymphoid and Plasma Cell TumourLymphoid and Plasmacytic NeoplasmLymphoid and Plasmacytic TumourMMAC1MMAC1 proteinMalignant NeoplasmsMalignant Soft Tissue NeoplasmMalignant TumorMeasuresMiceMice MammalsModelingModern ManMolecularMurineMusMutated in Multiple Advanced Cancers 1MutationOncogenicOncoprotein p53Operative ProceduresOperative Surgical ProceduresP53PD 1PD-1PD-1 inhibitorsPD1PD1 inhibitorsPHTS genePHTS proteinPTENPTEN genePTEN proteinPTEN1PatientsPb elementPenetrancePhosphatase and Tensin HomologPhosphatase and Tensin Homolog Deleted on Chromosome 10Phosphoprotein P53Phosphoprotein pp53Pilot ProjectsPlayPopulationPre-Clinical ModelPreclinical ModelsPreclinical TestingProgression-Free SurvivalsProtein TP53ProteinsRecurrenceRecurrentRemovalReportingResearchRoleSarcomaSoft tissue sarcomaSolid NeoplasmSolid TumorStomasStrains Cell LinesSurgicalSurgical InterventionsSurgical ProcedureSurgical RemovalT memory cellT-Cell SubsetsT-CellsT-LymphocyteT-Lymphocyte SubsetsTP53TP53 geneTRP53TamoxifenTertiary lymphoid structureTestingTissue GrowthTissuesTransgenic MiceTumor CellTumor ImmunityTumor Protein p53Tumor Protein p53 GeneValidationWorkanti programmed cell death protein 1 inhibitoranti-PD-1 inhibitorsanti-PD1 inhibitorsanti-tumor immune responseanti-tumor immunityantitumor immunitycancer immunitycancer microenvironmentchemotherapyclinical interventionclinical therapycultured cell linedevelopmentaleffective therapyeffective treatmentgenetically engineered mouse modelgenetically engineered murine modelgenome mutationheavy metal Pbheavy metal leadhigh riskhost responsehuman dataimmune check point inhibitorimmune competentimmune drugsimmune microenvironmentimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic therapeuticsimmunoresponseimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimmunotherapeuticsimmunotherapy agentimprovedin vivoinduced Creinducible Creinhibitorinnovateinnovationinnovativeinsightliposarcomalymphoid neoplasmmalignancymalignant soft tissue tumormemory T lymphocytemouse modelmurine modelmutated in multiple advanced cancers 1 proteinneoplasm/cancerneoplastic cellnovelontogenyoverexpressoverexpressionp53 Antigenp53 Genesp53 Tumor Suppressorphase 2 trialphase II trialphosphatase and tensin homologue on chromosome tenpilot studypre-clinical studypre-clinical testingpreclinical studyprogrammed cell death 1programmed cell death protein 1programmed death 1protein p53resectionresident memory T cellresponsesle2social rolesurgerysystemic lupus erythematosus susceptibility 2tertiary lymphoid organthymus derived lymphocytetissue resident memory T celltrial regimentrial treatmenttumortumor immune microenvironmenttumor microenvironmenttumor-immune system interactionsvalidations
Applications closed.
Description preview
PROJECT SUMMARY/ABSTRACT
Liposarcoma (LPS) is the most common type of soft tissue sarcoma. The most common subtypes are well-
differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma which are characterized by genomic
amplification of murine double minute 2 (MDM2), a negative regulator of p53, in over 90% of cases, while 7% of
human…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click